{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T13:33:21Z","timestamp":1790948001440,"version":"4.1.0"},"reference-count":39,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalmicrobiologyandinfection.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Microbiology and Infection"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.cmi.2023.09.002","type":"journal-article","created":{"date-parts":[[2023,9,9]],"date-time":"2023-09-09T04:56:38Z","timestamp":1694235398000},"page":"51-58","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["The effect of antibiotic therapy for Clostridioides difficile infection on mortality and other patient-relevant outcomes: a systematic review and meta-analysis"],"prefix":"10.1016","volume":"30","author":[{"given":"Yoav","family":"Stabholz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mical","family":"Paul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cmi.2023.09.002_bib1","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1186\/s12879-016-1610-3","article-title":"Epidemiological and economic burden of Clostridium difficile in the United States: estimates from a modeling approach","volume":"16","author":"Desai","year":"2016","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.cmi.2023.09.002_bib3","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1017\/ice.2016.188","article-title":"Mortality and costs in Clostridium difficile infection among the elderly in the United States","volume":"37","author":"Shorr","year":"2016","journal-title":"Infect Control Hosp Epidemiol"},{"key":"10.1016\/j.cmi.2023.09.002_bib4","series-title":"Report to the president on combating antibiotic resistance","author":"President\u2019s Council of Advisors on Science and Technology","year":"2014"},{"key":"10.1016\/j.cmi.2023.09.002_bib5","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/cix1085","article-title":"Clinical practice guidelines for Clostridium difficile infection in adults and children: 2017 update by the infectious diseases society of America (IDSA) and society for Healthcare Epidemiology of America (SHEA)","volume":"66","author":"McDonald","year":"2018","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2023.09.002_bib6","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1093\/cid\/ciab718","article-title":"Clinical practice guideline by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA): 2021 focused update guidelines on management of Clostridioides difficile infection in adults","volume":"73","author":"Johnson","year":"2021","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2023.09.002_bib7","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.cmi.2021.09.038","article-title":"European Society of Clinical Microbiology and Infectious Diseases: 2021 update on the treatment guidance document for Clostridioides difficile infection in adults","volume":"27","author":"van Prehn","year":"2021","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cmi.2023.09.002_bib8","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.cmi.2014.08.017","article-title":"Recurrent Clostridium difficile infection is associated with increased mortality","volume":"21","author":"Olsen","year":"2015","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cmi.2023.09.002_bib9","first-page":"CD004610","article-title":"Antibiotic treatment for Clostridium difficile-associated diarrhoea in adults","volume":"3","author":"Nelson","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.cmi.2023.09.002_bib10","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1007\/s00228-022-03376-1","article-title":"Real-world comparison of fidaxomicin versus vancomycin or metronidazole in the treatment of Clostridium difficile infection: a systematic review and meta-analysis","volume":"78","author":"Dai","year":"2022","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.cmi.2023.09.002_bib11","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1007\/s15010-022-01778-y","article-title":"Non-inferiority of metronidazole to vancomycin in the treatment of first episode non-severe Clostridioides difficile infection: a single center retrospective cohort study","volume":"50","author":"Najjar-Debbiny","year":"2022","journal-title":"Infection"},{"key":"10.1016\/j.cmi.2023.09.002_bib12","author":"Lefebvre"},{"key":"10.1016\/j.cmi.2023.09.002_bib13","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.cmi.2023.09.002_bib14","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/S0140-6736(83)91036-X","article-title":"Prospective randomised trial of metronidazole versus vancomycin for Clostridium-difficile-associated diarrhoea and colitis","volume":"2","author":"Teasley","year":"1983","journal-title":"Lancet"},{"key":"10.1016\/j.cmi.2023.09.002_bib15","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1093\/clinids\/22.5.813","article-title":"Comparison of vancomycin, teicoplanin, metronidazole, and fusidic acid for the treatment of Clostridium difficile-associated diarrhea","volume":"22","author":"Wenisch","year":"1996","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2023.09.002_bib16","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1053\/j.gastro.2018.12.019","article-title":"Fecal microbiota transplantation is superior to fidaxomicin for treatment of recurrent Clostridium difficile infection","volume":"156","author":"Hvas","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cmi.2023.09.002_bib17","doi-asserted-by":"crossref","first-page":"s72","DOI":"10.1017\/ash.2022.195","article-title":"Comparison of fidaxomicin to oral vancomycin for the treatment of Clostridioides difficile infection in hospitalized patients","volume":"2","author":"Rao","year":"2022","journal-title":"Antimicrob Steward Healthc Epidemiol"},{"key":"10.1016\/j.cmi.2023.09.002_bib18","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1086\/519265","article-title":"A\u00a0comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity","volume":"45","author":"Zar","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2023.09.002_bib19","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1056\/NEJMoa0910812","article-title":"Fidaxomicin versus vancomycin for Clostridium difficile infection","volume":"364","author":"Louie","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2023.09.002_bib20","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S1473-3099(11)70374-7","article-title":"Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial","volume":"12","author":"Cornely","year":"2012","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.cmi.2023.09.002_bib21","series-title":"A\u00a0phase IIIb\/IV randomized, controlled, double-blind, double-dummy, parallel group study to compare the efficacy of fidaxomicin to vancomycin in the sustained clinical cure of Clostridium difficile infection in adults receiving immunosuppressive therapy","author":"Astellas Pharma","year":"2013"},{"key":"10.1016\/j.cmi.2023.09.002_bib22","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1093\/cid\/ciu313","article-title":"Vancomycin, metronidazole, or tolevamer for Clostridium difficile infection: results from two multinational, randomized, controlled trials","volume":"59","author":"Johnson","year":"2014","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2023.09.002_bib23","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1017\/ice.2015.270","article-title":"Assessment of Clostridium difficile burden in patients over time with first episode infection following fidaxomicin or vancomycin","volume":"37","author":"Housman","year":"2016","journal-title":"Infect Control Hosp Epidemiol"},{"key":"10.1016\/j.cmi.2023.09.002_bib24","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/S1473-3099(17)30751-X","article-title":"Extended-pulsed fidaxomicin versus vancomycin for Clostridium difficile infection in patients 60 years and older (EXTEND): a randomised, controlled, open-label, phase 3b\/4 trial","volume":"18","author":"Guery","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.cmi.2023.09.002_bib25","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/j.jiac.2018.05.010","article-title":"Efficacy and safety of fidaxomicin for the treatment of Clostridioides (Clostridium) difficile infection in a randomized, double-blind, comparative Phase III study in Japan","volume":"24","author":"Mikamo","year":"2018","journal-title":"J\u00a0Infect Chemother"},{"key":"10.1016\/j.cmi.2023.09.002_bib27","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s12941-016-0140-6","article-title":"A\u00a0pilot study to assess bacterial and toxin reduction in patients with Clostridium difficile infection given fidaxomicin or vancomycin","volume":"15","author":"Thabit","year":"2016","journal-title":"Ann Clin Microbiol Antimicrob"},{"key":"10.1016\/j.cmi.2023.09.002_bib28","doi-asserted-by":"crossref","first-page":"ofaa157","DOI":"10.1093\/ofid\/ofaa157","article-title":"Efficacy of bezlotoxumab in participants receiving metronidazole, vancomycin, or fidaxomicin for treatment of Clostridioides (Clostridium) difficile infection","volume":"7","author":"Dubberke","year":"2020","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.cmi.2023.09.002_bib29","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.jhin.2020.09.025","article-title":"Risk of complications and mortality following recurrent and non-recurrent Clostridioides difficile infection: a retrospective observational database study in England","volume":"106","author":"Enoch","year":"2020","journal-title":"J\u00a0Hosp Infect"},{"key":"10.1016\/j.cmi.2023.09.002_bib30","doi-asserted-by":"crossref","first-page":"299","DOI":"10.3390\/antibiotics10030299","article-title":"Mortality following Clostridioides difficile infection in Europe: a retrospective multicenter case-control study","volume":"10","author":"Czepiel","year":"2021","journal-title":"Antibiotics (Basel)"},{"key":"10.1016\/j.cmi.2023.09.002_bib31","doi-asserted-by":"crossref","first-page":"3195","DOI":"10.1111\/j.1572-0241.2008.02198.x","article-title":"Clinical review of the management of fulminant Clostridium difficile infection","volume":"103","author":"Jaber","year":"2008","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cmi.2023.09.002_bib32","doi-asserted-by":"crossref","DOI":"10.1177\/17562848221078441","article-title":"Health-related quality of life in patients with recurrent Clostridioides difficile infections","volume":"15","author":"Hammeken","year":"2022","journal-title":"Therap Adv Gastroenterol"},{"key":"10.1016\/j.cmi.2023.09.002_bib33","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1016\/j.jiac.2022.08.008","article-title":"Oral fidaxomicin versus vancomycin for the treatment of Clostridioides difficile infection: a systematic review and meta-analysis of randomized controlled trials","volume":"28","author":"Tashiro","year":"2022","journal-title":"J\u00a0Infect Chemother"},{"key":"10.1016\/j.cmi.2023.09.002_bib34","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.jiac.2019.07.005","article-title":"Fidaxomicin compared with vancomycin and metronidazole for the treatment of Clostridioides (Clostridium) difficile infection: a network meta-analysis","volume":"26","author":"Okumura","year":"2020","journal-title":"J\u00a0Infect Chemother"},{"key":"10.1016\/j.cmi.2023.09.002_bib35","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1086\/665712","article-title":"Potential for transmission of Clostridium difficile by asymptomatic acute care patients and long-term care facility residents with prior C.\u00a0difficile infection","volume":"33","author":"Jinno","year":"2012","journal-title":"Infect Control Hosp Epidemiol"},{"key":"10.1016\/j.cmi.2023.09.002_bib36","doi-asserted-by":"crossref","first-page":"16","DOI":"10.5009\/gnl18071","article-title":"Recurrent Clostridium difficile infection: risk factors, treatment, and prevention","volume":"13","author":"Song","year":"2019","journal-title":"Gut Liver"},{"key":"10.1016\/j.cmi.2023.09.002_bib37","doi-asserted-by":"crossref","first-page":"S93","DOI":"10.1093\/cid\/cis499","article-title":"Fidaxomicin versus vancomycin for Clostridium difficile infection: meta-analysis of pivotal randomized controlled trials","volume":"55","author":"Crook","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2023.09.002_bib38","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1002\/phar.2734","article-title":"Path of least recurrence: a systematic review and meta-analysis of fidaxomicin versus vancomycin for Clostridioides difficile infection","volume":"42","author":"Liao","year":"2022","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.cmi.2023.09.002_bib39","doi-asserted-by":"crossref","first-page":"e259","DOI":"10.1016\/S1473-3099(23)00047-6","article-title":"Redefining Clostridioides difficile infection antibiotic response and clinical outcomes","volume":"23","author":"Gonzales-Luna","year":"2023","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.cmi.2023.09.002_bib40","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.ijid.2022.09.013","article-title":"Clostridioides difficile infection: are the three currently used antibiotic treatment options equal from pharmacological and microbiological points of view?","volume":"124","author":"Krutova","year":"2022","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.cmi.2023.09.002_bib41","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1093\/jac\/dkt302","article-title":"In\u00a0vitro selection, via serial passage, of Clostridium difficile mutants with reduced susceptibility to fidaxomicin or vancomycin","volume":"69","author":"Leeds","year":"2014","journal-title":"J\u00a0Antimicrob Chemother"}],"container-title":["Clinical Microbiology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X23004202?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X23004202?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T07:37:47Z","timestamp":1761118667000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1198743X23004202"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["S1198743X23004202"],"URL":"https:\/\/doi.org\/10.1016\/j.cmi.2023.09.002","relation":{},"ISSN":["1198-743X"],"issn-type":[{"value":"1198-743X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The effect of antibiotic therapy for Clostridioides difficile infection on mortality and other patient-relevant outcomes: a systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Clinical Microbiology and Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cmi.2023.09.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.cmi.2023.10.015","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"https:\/\/doi.org\/10.1016\/j.cmi.2023.10.028","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}